Resolve Scores The Option Of An Exit With Takeda Tie-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Resolve Therapeutics and Takeda Pharmaceuticals have agreed to an option agreement that will add to the Japanese pharma’s immunology pipeline while also providing a path to an eventual exit for the biotech’s investors.
You may also be interested in...
Start-Up Quarterly Statistics, Q1 2013
Start-up company fundraising got off to a slow start in 2013: life sciences companies brought in $398.7 million, roughly 59% less than in the final quarter of 2012. Of the total raised, 84% went to biopharmas. The majority of start-up alliances were for discovery- or preclinical-stage products and there were four start-up acquisitions for the quarter – three in biopharma and one in the medical device sector.
Deals Of The Week: Mylan/Agila, UCB/Biotie, Jazz/Concert…
Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.
Takeda’s Strategic Run Up To Nycomed
With the acquisition of Nycomed, Takeda’s long-standing strategy for becoming a world-class pharma has come into focus. The company spent much of the past decade building up its pipeline, globalizing R&D and importing Western staff, assets, platforms and processes. It also began a hectic period of M&A unparalleled among Japanese companies, culminating in 2011 with its acquisition of Nycomed. Now its focus will need to shift from big acquisitions and organizational makeover to execution.